MCLA-128可对抗融合阳性癌症。
MCLA-128 Fights Fusion-Positive Cancers.
出版信息
Cancer Discov. 2019 Dec;9(12):1636. doi: 10.1158/2159-8290.CD-NB2019-128. Epub 2019 Nov 4.
Abstract
Two patients with -wild-type pancreatic ductal carcinoma and fusions received the bispecific antibody MCLA-128, which led to tumor shrinkage. One experienced a partial response and the other had stable disease. A third patient with non-small cell lung cancer and an NRG1 fusion also experienced a partial response in a clinical proof-of-concept study.
摘要
两名患有野生型胰腺导管癌且存在融合现象的患者接受了双特异性抗体MCLA-128治疗，这导致肿瘤缩小。其中一名患者出现部分缓解，另一名患者病情稳定。在一项临床概念验证研究中，第三名患有非小细胞肺癌且存在NRG1融合的患者也出现了部分缓解。
Zotero 插件